Avalo Therapeutics(US:AVTX)2026-03-23 11:01Financial Performance - Cash, cash equivalents, and short-term investments were approximately $98.3 million as of December 31, 2025, expected to fund operations into 2028[6] - Research and development expenses increased to $50.1 million for the year ended December 31, 2025, up from $24.4 million in 2024, driven by the LOTUS trial[6] - General and administrative expenses rose to $22.9 million for the year ended December 31, 2025, an increase of $5.7 million from 2024[7] - Net loss for the year ended December 31, 2025, was $78.3 million, compared to a net loss of $35.1 million in 2024[7] - Basic and diluted net loss per share was $5.84 for the year ended December 31, 2025, compared to $7.94 in 2024[9] - Total revenues for 2025 were $59,000, a decrease from $441,000 in 2024[9] - Total operating expenses for 2025 were $72.98 million, compared to $68.95 million in 2024[9] - Total assets decreased to $116.5 million as of December 31, 2025, from $150.7 million in 2024[8] - Total stockholders' equity decreased to $83.0 million as of December 31, 2025, from $133.0 million in 2024[8] Clinical Trials and Development - Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is expected in Q2 2026[5] - The company is focused on the growth and strategy related to its clinical trials for abdakibart (AVTX-009) and other future product candidates[15] - Avalo is conducting the Phase 2 LOTUS trial, with expectations for clinical data readouts to be announced in the future[15] Risk Management - Avalo's management emphasizes that forward-looking statements are based on various assumptions and are subject to significant risks and uncertainties[15] - The company is assessing its anticipated operating expenses and cash runway to ensure sufficient funding for its operations[15] - Avalo acknowledges potential risks including drug development costs, trial timing, regulatory risks, and reliance on key personnel[15]